Technology Assessment

FDG Positron Emission Tomography for Evaluating Breast Cancer


Expand All | Collapse All


Positron emission tomography (PET) is a non-invasive imaging procedure used for measuring the concentrations of positron-emitting radioisotopes within the tissue of living subjects. 2-[F18] fluoro-2-deoxy-D-glucose (FDG) is a radiopharmaceutical that is attracted to higher areas of metabolism. On December 15, 2000, HCFA published a Decision Memorandum on a request for broad coverage (CAG-00065) of all oncological indications, heart disease, and neurological disorders. The December 15th decision memorandum stated that HCFA had insufficient evidence to support coverage for the indication of breast cancer at that time but would refer the issue to MCAC.

Technology Assessment

Download Technology Assessment [PDF, 805KB].

Other Material